Scancell Holdings Past Earnings Performance
Past criteria checks 0/6
Scancell Holdings's earnings have been declining at an average annual rate of -9.7%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 54.5% per year.
Key information
-9.7%
Earnings growth rate
5.6%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | 54.5% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Apr 2024 |
Revenue & Expenses Breakdown
How Scancell Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Apr 24 | 0 | -6 | 5 | 13 |
| 31 Jan 24 | 0 | -8 | 5 | 13 |
| 31 Oct 23 | 0 | -10 | 5 | 13 |
| 31 Jul 23 | 3 | -11 | 5 | 12 |
| 30 Apr 23 | 5 | -12 | 5 | 12 |
| 31 Jan 23 | 5 | -12 | 5 | 11 |
| 31 Oct 22 | 5 | -13 | 5 | 10 |
| 31 Jul 22 | 3 | -9 | 5 | 10 |
| 30 Apr 22 | 0 | -5 | 5 | 9 |
| 31 Jan 22 | 0 | -6 | 5 | 9 |
| 31 Oct 21 | 0 | -8 | 4 | 8 |
| 31 Jul 21 | 0 | -12 | 4 | 7 |
| 30 Apr 21 | 0 | -15 | 3 | 6 |
| 31 Jan 21 | 0 | -11 | 3 | 6 |
| 31 Oct 20 | 0 | -7 | 2 | 5 |
| 31 Jul 20 | 0 | -6 | 2 | 5 |
| 30 Apr 20 | 0 | -6 | 2 | 5 |
| 31 Jan 20 | 0 | -5 | 2 | 4 |
| 31 Oct 19 | 0 | -5 | 2 | 4 |
| 31 Jul 19 | 0 | -5 | 2 | 4 |
| 30 Apr 19 | 0 | -6 | 3 | 4 |
| 31 Jan 19 | 0 | -6 | 3 | 4 |
| 31 Oct 18 | 0 | -5 | 3 | 3 |
| 31 Jul 18 | 0 | -5 | 3 | 3 |
| 30 Apr 18 | 0 | -4 | 2 | 3 |
| 31 Jan 18 | 0 | -4 | 2 | 3 |
| 31 Oct 17 | 0 | -4 | 2 | 3 |
| 31 Jul 17 | 0 | -4 | 2 | 3 |
| 30 Apr 17 | 0 | -4 | 2 | 3 |
| 31 Jan 17 | 0 | -3 | 2 | 3 |
| 31 Oct 16 | 0 | -3 | 1 | 2 |
| 31 Jul 16 | 0 | -3 | 1 | 2 |
| 30 Apr 16 | 0 | -3 | 1 | 2 |
| 31 Jan 16 | 0 | -2 | 1 | 2 |
| 31 Oct 15 | 0 | -2 | 1 | 2 |
| 31 Jul 15 | 0 | -2 | 1 | 2 |
| 30 Apr 15 | 0 | -2 | 1 | 2 |
| 31 Jan 15 | 0 | -2 | 1 | 2 |
| 31 Oct 14 | 0 | -2 | 1 | 2 |
| 31 Jul 14 | 0 | -2 | 1 | 2 |
| 30 Apr 14 | 0 | -2 | 1 | 2 |
Quality Earnings: SCLP is currently unprofitable.
Growing Profit Margin: SCLP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SCLP is unprofitable, and losses have increased over the past 5 years at a rate of 9.7% per year.
Accelerating Growth: Unable to compare SCLP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SCLP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: SCLP's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.